Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRestructuring CostsSelling, General & Administrative
Others
Ratios

Pasithea Therapeutics (KTTA) Operating Expenses (2021 - 2024)

Pasithea Therapeutics (KTTA) has disclosed Operating Expenses for 4 consecutive years, with $3.3 million as the latest value for Q4 2024.

  • Quarterly Operating Expenses fell 36.69% to $3.3 million in Q4 2024 from the year-ago period, while the trailing twelve-month figure was $14.2 million through Dec 2024, down 10.82% year-over-year, with the annual reading at $20.9 million for FY2025, 46.37% up from the prior year.
  • Operating Expenses hit $3.3 million in Q4 2024 for Pasithea Therapeutics, up from $3.0 million in the prior quarter.
  • In the past five years, Operating Expenses ranged from a high of $5.1 million in Q4 2023 to a low of $549609.0 in Q1 2021.
  • Historically, Operating Expenses has averaged $2.9 million across 4 years, with a median of $3.1 million in 2023.
  • Biggest five-year swings in Operating Expenses: surged 397.01% in 2022 and later crashed 36.69% in 2024.
  • Year by year, Operating Expenses stood at $2.0 million in 2021, then surged by 106.89% to $4.0 million in 2022, then grew by 27.36% to $5.1 million in 2023, then plummeted by 36.69% to $3.3 million in 2024.
  • Business Quant data shows Operating Expenses for KTTA at $3.3 million in Q4 2024, $3.0 million in Q3 2024, and $3.9 million in Q2 2024.